My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 8 451 / DOI: 10.3332/ecancer.2014.451


NHS reforms in England: the implications for chemotherapy commissioning

For oncology, one of the biggest effects of the reforms to the National Health Service (NHS) in England has been the designation of systemic anticancer treatments (other than hormonal agents) as a specialised service. This means that all decisions regarding the commissioning of chemotherapy are made at the national level via NHS England (NHSE), under expert guidance from the Chemotherapy Clinical Reference Group (CRG). Commissioning decisions will be based on several factors, not only clinical efficacy and cost/affordability, but also the ‘added value’ that a new treatment may offer in terms of patient outcomes, resource utilisation, and/or wider benefits to society. Oncology health-care professionals (HCPs) are in a position to affect cancer commissioning decisions in the reformed NHS, not only the small number who are members of the Chemotherapy CRG, but also as advisors to the Chemotherapy CRG via disease-specific consensus work, and through participation in the collection and reporting of real-life data on patient outcomes. With the emerging emphasis on both consensus work and outcomes data, a step change can also be expected in the relationship between HCPs and the pharmaceutical industry, including a strengthened role for non-promotional education, support for forums and consensus groups, and facilitation of the development, collection, and dissemination of findings from real-life practice. In addition, there will be an onus on the pharmaceutical industry to provide information on the implications that new products may have for service delivery and capacity and for meeting patients’ and society’s expectations. This information will need to be developed and delivered in a timely way, well in advance of the launch of a new product.

Keywords: Cancer Drugs Fund, Clinical Commissioning Groups, Clinical Reference Groups, NHS England, systemic anticancer treatment, value-based assessment


Economics Medicines

Loading Article Metrics ... Please wait

Related articles

Policy: Phosphoethanolamine and the danger of unproven drugs

Abstract | Full Article | PDF | Portuguese Published: 17 Oct 2016 / DOI: 10.3332/ecancer.2016.681

Clinical Study: Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Abstract | Full Article | PDF Published: 12 Oct 2016 / DOI: 10.3332/ecancer.2016.680

Conference Report: Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

Abstract | Full Article | PDF | Spanish Published: 06 Sep 2016 / DOI: 10.3332/ecancer.2016.672

Conference Report: Highlights from the 2016 WIN Symposium, 27–29 June 2016, Paris: personalised therapy beyond next-generation sequencing

Abstract | Full Article | PDF Published: 24 Aug 2016 / DOI: 10.3332/ecancer.2016.669

Conference Report: Children’s palliative care now! Highlights from the second ICPCN conference on children’s palliative care, 18–21 May 2016, Buenos Aires, Argentina

Abstract | Full Article | PDF | Spanish Published: 23 Aug 2016 / DOI: 10.3332/ecancer.2016.667

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence